- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Morgan Stanley Raises BridgeBio Pharma Price Target to $98
Analysts see continued growth potential for the clinical-stage biotech company.
Published on Feb. 28, 2026
Got story updates? Submit your updates here. ›
BridgeBio Pharma (NASDAQ:BBIO) had its price target increased from $96.00 to $98.00 by Morgan Stanley analysts, who maintained their 'overweight' rating on the stock. The analysts cited the company's progress in its pipeline of genetic disease and cancer treatments as reasons for the higher target.
Why it matters
BridgeBio is a closely watched clinical-stage biotech company focused on developing transformative medicines for patients with genetic diseases and cancers. The increased price target from a major investment bank signals continued optimism about the company's growth potential as it advances its diverse pipeline of therapies.
The details
Morgan Stanley analysts raised their price target on BridgeBio Pharma after the company reported its latest financial results. Several other analysts have also issued positive ratings and price targets on BridgeBio in recent months, reflecting the company's progress in its drug development efforts.
- BridgeBio Pharma reported its Q4 2025 financial results on February 24, 2026.
The players
Morgan Stanley
A global financial services firm that provides investment banking, securities, wealth management and investment management services.
BridgeBio Pharma
A clinical-stage biopharmaceutical company headquartered in Palo Alto, California that is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The increased price target from Morgan Stanley reflects the investment community's ongoing confidence in BridgeBio's ability to advance its diverse pipeline of genetic disease and cancer treatments, underscoring the company's potential to deliver transformative medicines for patients in need.
